Compare Organon & Co. Common Stock (OGN) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Direxion Daily TSLA Bull 2X Shares trades at $9.31 (market cap $3.84B). The key difference: Organon & Co. Common Stock and Direxion Daily TSLA Bull 2X Shares are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| OGN | TSLL | |
|---|---|---|
Market Cap | $3.62B | $3.84B |
Volume | 2,892,999 | 36,217,346 |
Sector | Health | Leveraged / Inverse |
52-Week High | $13.81 | $23.03 |
52-Week Low | $5.70 | $6.74 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.00, down 1.48% on the day, reflecting amplified exposure to Tesla's volatility. The technical outlook is mixed with a neutral overall signal, while recent news highlights its sensitivity to Tesla-specific catalysts like the Cybercab event. Financial ratios are not applicable as this is a leveraged ETF tracking Tesla's daily performance.
The outlook for TSLL is directly tied to Tesla's stock momentum, offering potential for magnified gains but carrying high risk from daily rebalancing and volatility decay. Investors face significant downside risk if Tesla trends lower, making it suitable only for short-term, risk-tolerant traders monitoring Tesla's news flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
